دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Racial Difference in Efficacy of Golimumab in Ulcerative Colitis
Ruby Greywoode, MD, Francesca Petralia, PhD, Thomas A Ullman, MD, Jean Frederic Colombel, MD, Ryan C Ungaro, MD, MS
doi : 10.1093/ibd/izac161
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 843–849
Single-cell Expression Atlas Reveals Cell Heterogeneity in the Creeping Fat of Crohn’s Disease
Weigang Shu, MD, Yongheng Wang, MD, Chuanding Li, MD, Lei Zhang, MD, Deji Zhuoma, MD, Pengyu Yang, MD, Guorong Yan, MD, PhD, Chunqiu Chen, MD, PhD, Yongbing Ba, MD, PhD, Peng Du, MD, PhD, Xiaolei Wang, MD, PhD
doi : 10.1093/ibd/izac266
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 850–865
Creeping fat (CrF) has been recognized to play a positive role in Crohn’s disease (CD) progression, yet the cellular compositions within mesenteric adipose tissue (MAT) and their potential mechanism in CrF formation are poorly understood.
Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn’s Disease: Real-world Experience From a Large Canadian Center
Rocio Sedano, MD, Leonardo Guizzetti, PhD, Cassandra McDonald, Melanie Beaton, MD, Nilesh Chande, MD, Jamie Gregor, MD, Michael Sey, MD, Aze Wilson, MD, PhD, Vipul Jairath, MD, PhD
doi : 10.1093/ibd/izac149
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 866–874
With the expanding therapeutic armamentarium for inflammatory bowel disease (IBD), real-world data may help inform drug positioning. We assessed clinical, endoscopic, imaging, and biochemical response/remission outcomes in patients with Crohn’s disease (CD) treated with ustekinumab in a large Canadian IBD center.
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease
Emily C L Wong, BHSc, Arif Yusuf, MD, Jagoda Pokryszka, MD, Parambir S Dulai, MD, Jean-Frederic Colombel, MD, John K Marshall, MD, MSc, Walter Reinisch, MD, PhD, Neeraj Narula, MD, MPH
doi : 10.1093/ibd/izac157
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 875–882
The terminal ileum poses a predilection for Crohn’s disease (CD) but is less susceptible to undergo healing to treatment with biologics and small molecules. This study aimed to evaluate histologic features associated with endoscopic remission (ER).
Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD
Dalin Li, PhD, Philip Debbas, Angela Mujukian, MD, Susan Cheng, MD, MS, Jonathan Braun, MD, Dermot P B McGovern, MD, PhD, Gil Y Melmed, MD, MS, CORALE-IBD Study Group
doi : 10.1093/ibd/izac174
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 883–887
The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.
Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection
Jordan E Axelrad, MD, MPH, Terry Li, MD, Salam P Bachour, MD, Takahiro I Nakamura, MD, Ravi Shah, MD, Michael C Sachs, PhD, Shannon Chang, MD, MBA, David P Hudesman, MD, Stefan D Holubar, MD, MS, Amy L Lightner, MD, Edward L Barnes, MD, MPH, Benjamin L Cohen, MD, MAS, Florian Rieder, MD, Eren Esen, MD, Feza Remzi, MD, Miguel Regueiro, MD, Benjamin Click, MD, MS
doi : 10.1093/ibd/izac158
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 888–897
Postoperative recurrence (POR) of Crohn’s disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR).
Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
Yoram Bouhnik, MD, PhD, Raja Atreya, MD, PhD, Daniel Casey, BMBCh, Michał Górecki, MSc, Deborah Baik, MS, Sang Wook Yoon, PhD, Taek Sang Kwon, BSc, Minyoung Jang, MS
doi : 10.1093/ibd/izac160
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 898–913
Inflammatory bowel disease (IBD) guidelines recommend tumor necrosis factor-α inhibitors (TNFis) for patients who have not responded to conventional therapy, and vedolizumab in case of inadequate response to conventional therapy and/or TNFis.
Patients With Stricturing or Penetrating Crohn’s Disease Phenotypes Report High Disease Burden and Treatment Needs
Yanni Fan, MS, MA, DSc, Ling Zhang, MS, MPH, Negar Omidakhsh, PhD, Rhonda L Bohn, MPH, ScD, Jennifer S Thompson, MD, Kimberly G Brodovicz, DrPH, Parakkal Deepak, MS, MBBS
doi : 10.1093/ibd/izac162
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 914–922
Crohn’s disease (CD) is a chronic autoimmune disease in which inflammation can progress to complications of stricturing and/or penetrating disease. Real-world data on burden of complicated CD phenotypes are limited.
Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers
Pauline Rivière, MD, Caitlyn Kanters, MSc, Gauthier Pellet, MD, Alexander Ni, MSc, Marianne Hupé, MD, Nesrine Aboulhamid, MSc, Florian Poullenot, MD, Alain Bitton, MD, PhD, Frank Zerbib, MD, PhD, Peter L Lakatos, MD, PhD, Waqqas Afif, MD, PhD, David Laharie, MD, PhD, Talat Bessissow, MD, PhD
doi : 10.1093/ibd/izac167
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 923–931
Real-life data on the efficacy of ustekinumab as first-line therapy for the treatment of luminal Crohn’s disease (CD) compared with anti-tumor necrosis factor (anti-TNF) agents are lacking. We compared the clinical response rates at 3 months in 2 cohorts of biologic-naïve patients treated by ustekinumab and anti-TNF agents.
Prevalence of Clostridioides difficile Infection After Ileal Pouch-anal Anastomosis in Patients With Chronic Antibiotic-dependent Pouchitis and Crohn’s-like Disease of the Pouch
Brandon M Shore, MD, Kimberly N Weaver, MD, Jessica R Allegretti, MD, MPH, Hans H Herfarth, MD, PhD, Edward L Barnes, MD, MPH
doi : 10.1093/ibd/izac165
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 932–937
Recurrent or chronic antibiotic therapy is a therapeutic hallmark of chronic antibiotic-dependent pouchitis (CADP) or Crohn’s-like disease of the pouch. Antibiotics alter the gut microbiome, which may increase the risk of Clostridioides difficile infection (CDI). The aim of this study was to determine the prevalence of CDI in patients with CADP and Crohn’s-like disease of the pouch.
Risk Variants in or Near ZBTB40 AND NFATC1 Increase the Risk of Both IBD and Adverse Bone Health Outcomes Highlighting Common Genetic Underpinnings Across Both Diseases
Kelly C Cushing, MD, MSCI, Yanhua Chen, PhD, MS, Xiaomeng Du, MS, Vincent Chen, MD, MS, Annapurna Kuppa, MS, Peter Higgins, MD, PhD, MSc, Elizabeth K Speliotes, MD, PhD, MPH
doi : 10.1093/ibd/izac273
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 938–945
Inflammatory bowel disease (IBD) is associated with an increased risk of osteoporosis and bone fracture. The aims of this study were to (1) confirm the association between IBD and low bone density and (2) test for shared risk variants across diseases.
STING Promotes Intestinal IgA Production by Regulating Acetate-producing Bacteria to Maintain Host-microbiota Mutualism
Tianming Yu, MD, Wenjing Yang, MD, PhD, Suxia Yao, MD, Yanbo Yu, MD, Maki Wakamiya, PhD, George Golovko, PhD, Yingzi Cong, PhD
doi : 10.1093/ibd/izac268
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 946–959
Intestinal Immunoglobulin A (IgA) is crucial in maintaining host-microbiota mutualism and gut homeostasis. It has been shown that many species of gut bacteria produce cyclic dinucleotides, along with an abundance of microbiota-derived DNA present within the intestinal lumen, which triggers the tonic activation of the cytosolic cGAS-STING pathway.
Early Life Stress in Mice Leads to Impaired Colonic Corticosterone Production and Prolonged Inflammation Following Induction of Colitis
Rachel Q Muir, BS, Barbara J Klocke, MS, Melissa S Jennings, BS, Patrick A Molina, PhD, Jung-Shan Hsu, MS, Cailin E Kellum, BS, Katie L Alexander, PhD, Goo Lee, MD, Jeremy B Foote, DVM, PhD, Robin G Lorenz, MD, PhD, Jennifer S Pollock, PhD, Craig L Maynard, PhD
doi : 10.1093/ibd/izac280
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 960–972
Early life stress (ELS) is an environmental trigger believed to promote increased risk of IBD. Our goal was to identify mechanisms whereby ELS in mice affects susceptibility to and/or severity of gut inflammation.
Alterations in the Course of Inflammatory Bowel Disease Following Liver Transplantation: A Systematic Review and Meta-analysis
Ali Reza Safarpour, PhD, Sara Shojaei-Zarghani, PhD, Manoosh Mehrabi, PhD, Abbas Ali Keshtkar, PhD, Ali Akbar Oroojan, PhD, Gholam Reza Sivandzadeh, MD
doi : 10.1093/ibd/izac132
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 973–985
This study aimed to systematically review and pool data regarding the alterations in the clinical course of inflammatory bowel disease (IBD) following liver transplantation (LT).
Deep Dive Into MicroRNAs in Inflammatory Bowel Disease
Jaber Alfaifi, MBBS, MPH, Adeline Germain, MD, PhD, Anne-Charlotte Heba, MSc, Djésia Arnone, PharmD, PhD, Laura Gailly, BSc, Ndeye Coumba Ndiaye, PhD, Emilie Viennois, PhD, Bénédicte Caron, MD, PhD, Laurent Peyrin-Biroulet, MD, PhD, Natacha Dreumont, PhD
doi : 10.1093/ibd/izac250
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 986–999
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is thought to develop in genetically predisposed individuals as a consequence of complex interactions between dysregulated inflammatory stimuli, immunological responses, and environmental factors. The pathogenesis of IBD has yet to be fully understood.
Rectally Administrated Thioguanine for Distal Ulcerative Colitis: A Multicenter Case Series
Femke Crouwel, MD, Melek Simsek, MD, Amarylle S van Doorn, BSc, Chris J J Mulder, MD, PhD, Hans J C Buiter, PharmD, PhD, Murray L Barclay, MD, FRACP, Timothy H Florin, MD, Nanne K de Boer, MD, PhD
doi : 10.1093/ibd/izac195
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 1000–1004
Inflammatory Bowel Disease and Helicobacter pylori: Protective or Present?
Samuel Tanner, MD, Jeffry Katz, MD, Fabio Cominelli, MD, PhD, Miguel Regueiro, MD, Gregory Cooper, MD, Emad Mansoor, MD
doi : 10.1093/ibd/izac202
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 1005–1007
Solitary Rectal Ulcer Syndrome Coexisting with Colitis Cystica Profunda—Is Mucosal Resection Radical or Not?
Yajie Zhang, MD, PhD, Feng Tian, MD, PhD, Hui Li, MD, PhD
doi : 10.1093/ibd/izac232
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 1008–1009
Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis
Florence-Damilola Odufalu
doi : 10.1093/ibd/izac179
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 1010–1011
Revisiting Drug Development for Older Molecules in IBD
Paula Sousa, MD, Nurulamin M Noor, MRCP
doi : 10.1093/ibd/izac220
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages 1012–1013
To Be in Remission or in Corticosteroid-free Remission: That Is the Question for Women With Inflammatory Bowel Disease at Conception
Reiko Kunisaki, MD, PhD, Aya Ikeda, MD, Katsuki Yaguchi, MD, Misa Onishi, MD, Shunsuke Shibui, MD, Daisuke Nishida, MD, Akira Madarame, MD, PhD, Kenichiro Toritani, MD, PhD, Yoshinori Nakamori, MD, Masafumi Nishio, MD, PhD, Tsuyoshi Ogashiwa, MD, Ayako Fujii, MD, Hideaki Kimura, MD, PhD, Ryoichi Suzuki, MD, PhD, Shigeru Aoki, MD, PhD, Shin Maeda, MD, PhD
doi : 10.1093/ibd/izad023
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages e20–e21
Coronary Artery Plaque Assessment by CT Angiogram in Inflammatory Bowel Disease
Malek Ayoub, MD, Harini Shah, BS, Bao Chau Nguyen, MD, Maahum Mehdi, BS, Sneha Nagavally, MS, April Dawson, PhD, MPH, Sadeer Al-Kindi, MD, Salim Virani, MD, PhD, Divyanshu Mohananey, MD, Abhinav Sharma, MD, Preetika Sinh, MD
doi : 10.1093/ibd/izad036
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages e22–e24
Causal Relationship Between Estimated Glomerular Filtration Rate and Inflammatory Bowel Disease: Genetic Evidence From Bidirectional Mendelian Randomization Analysis
Mengsi Liu, MBBS, Zhen Ye, MBBS, Zhen Sun, MBBS
doi : 10.1093/ibd/izad067
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages e25–e27
Reply: Causal Relationship Between Estimated Glomerular Filtration Rate and Inflammatory Bowel Disease: Genetic Evidence From Bidirectional Mendelian Randomization Analysis
Yuanhang Yang, MD, MSc, Juan Jesus Carrero, PhD
doi : 10.1093/ibd/izad069
Inflammatory Bowel Diseases, Volume 29, Issue 6, June 2023, Pages e28–e29
